Xenogeneic immunosuppression of human umbilical cord mesenchymal stem cells in a major histocompatibility complex-mismatched allogeneic acute graft-versus-host disease murine model

European Journal of Haematology

Volumn 87, Issue 3, 2011, Pages 235-243

  Guo, Juan ^a   Yang, Jie ^b   Cao, Guofan ^b,c   Fan, Huahua ^b   Guo, Chenzhi ^b,c   Ma, Yue E ^b   Qian, Yanxiang ^d   Chen, Liang ^d   Li, Xiao ^a   Chang, Chunkang ^a  

^a SHANGHAI JIAO TONG UNIVERSITY AFFILIATED SIXTH PEOPLE S HOSPITAL   (China)

^b Shanghai Blood Center   (China)

^c EAST CHINA NORMAL UNIVERSITY   (China)

^d Cord blood stem cell bank in Shanghai ^*  (China)

Author keywords

Acute graft versus host disease; Arginase 1; Human umbilical cord mesenchymal stem cells; IFN ; Immunosuppression; Indoleamine 2,3 dioxygenase

Indexed keywords

GAMMA INTERFERON; TRANSFORMING GROWTH FACTOR BETA;

ACUTE GRAFT VERSUS HOST DISEASE; ADOPTIVE TRANSFER; ALLOGENIC BONE MARROW TRANSPLANTATION; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMMUNITY; MAJOR HISTOCOMPATIBILITY COMPLEX; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SPLEEN CELL; SURVIVAL; SURVIVAL TIME; UMBILICAL CORD;

ANIMALS; BONE MARROW TRANSPLANTATION; GRAFT VS HOST DISEASE; HISTOCOMPATIBILITY; HUMANS; IMMUNOSUPPRESSION; MAJOR HISTOCOMPATIBILITY COMPLEX; MESENCHYMAL STEM CELLS; MICE; MODELS, ANIMAL; TRANSPLANTATION, HETEROLOGOUS; TRANSPLANTATION, HOMOLOGOUS; UMBILICAL CORD;

EID: 84860413570     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2011.01635.x     Document Type: Article

References (29)

1. Le Blanc K, Frassoni F, Ball L, et al. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet 2008;371:1579-86.
2. Antin JH, Chen AR, Couriel DR, et al. Novel approaches to the therapy of steroid-resistant acute graft-versus-host disease. Biol Blood Marrow Transplant 2004;10:655-68.
3. Korngold B, Sprent J. Lethal graft-versus-host disease after bone marrow transplantation across minor histocompatibility barriers in mice. Prevention by removing mature T cells from marrow. J Exp Med 1978;148:1687.
4. Karahuseyinoglu S, Cinar O, Kilic E, et al. Biology of stem cells in human umbilical cord stroma: in situ and in vitro surveys. Stem Cells 2007;25:319-31.
5. Noel D, Djouad F, Bouffi C, et al. Multipotent mesenchymal stromal cells and immune tolerance. Leuk Lymphoma 2007;48:1283-9.
6. Wilson MT, Singh AK, Van Kaer L. Immunotherapy with ligands of natural killer T cells. Trends Mol Med 2002;8:225-31.
7. Tsuji M. Glycolipids and phospholipids as natural CD1d-binding NKT cell ligands. Cell Mol Life Sci 2006;63:1889-98.
8. Aggarwal S, Pittenger MF. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 2005;105:1815-22.
9. Polchert D, Sobinsky J, Douglas GW, et al. INF-γ activation of mesenchymal stem cells for treatment and prevention of graft versus host disease. Eur J Immunol 2008;38:1745-55.
10. Krampera M, Cosmi L, Angeli R, et al. Role for IFN-γ in the immunomodulatory activity of human bone marrow mesenchymal stem cells. Stem Cells 2006;24:386-98.
11. Meisel R, Zibert A, Laryea M, et al. Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2, 3-dioxygenase-mediated tryptophan degradation. Blood 2004;103:4619-21.
12. Ren GW, Zhang LY, Zhao X, et al. Mesenchymal stem cell-mediated immunosuppression occurs via concerted action of chemokines and nitric oxide. Cell Stem Cell 2008;2:141-50.
13. Ren GW, Su JJ, Zhang LY, et al. Species variation in the mechanisms of mesenchymal stem cell-mediated immunosuppression. Stem Cells 2009;27:1954-62.
14. Cooke KR, Kobzik L, Martin TR, et al. An experimental model of idiopathic pneumonia syndrome after bone marrow transplantation: I. The roles of minor H antigens and endotoxin. Blood 1996;88:3230-9.
15. Le Blanc K, Rasmusson I, Sundberg B, et al. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet 2004;363:1439-41.
16. Nauta AJ, Fibbe WE. Immunomodulatory properties of mesenchymal stromal cells. Blood 2007;110:3499-506.
17. Nauta AJ, Westerhuis G, Kruisselbrink AB, et al. Donor-derived mesenchymal stem cells are immunogenic in an allogeneic host and stimulate donor graft rejection in a nonmyeloablative setting. Blood 2006;108:2114-20.
18. Ringdén O, Uzunel M, Rasmusson I. Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease. Clin Transplant 2006;81:1390-7.
19. Ning H, Yang F, Jiang M, et al. The correlation between cotransplantation of mesenchymal stem cells and higher recurrence rate in hematologic malignancy patients: outcome of a pilot clinical study. Leukemia 2008;22:593-9.
20. Dominici M, Le Blanc K, Mueller I, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 2006;8:315-7.
21. Sato K, Ozaki K, Oh L, et al. Nitric oxide plays a critical role in suppression of T-cell proliferation by mesenchymal stem cells. Blood 2007;109:228-34.
22. Ryan JM, Barry F, Murphy JM, et al. Interferon-γ does not break, but promotes the immunosuppressive capacity of adult human mesenchymal stem cells. Clin Exp Immunol 2007;149:353-63.
23. Munn DH, Sharma MD, Baban B, et al. GCN2 kinase in T cells mediates proliferative arrest and energy induction in response to indoleamine 2, 3-dioxygenase. Immunity 2005;22:633-42.
24. Forouzandeh F, Jalili RB, Germain M, et al. Differential immunosuppressive effect of indoleamine 2, 3-dioxygenase (IDO) on primary human CD4(+) and CD8 (+) T cells. Mol Cell Biochem 2008;309:1-7.
25. Bronte V, Zanovello P. Regulation of immune responses by L-arginine metabolism. Nat Rev Immunol 2005;5:641-54.
26. Rodriguez PC, Ochoa AC. Arginine regulation by myeloid derived suppressor cells and tolerance in cancer: mechanisms and therapeutic perspectives. Immunol Rev 2008;222:180-91.
27. Ochoa AC, Zea AH, Hernandez C, Rodrguez PC. Arginase, prostaglandins, and myeloid-derived suppressor cells in renal cell carcinoma. Clin Cancer Res 2007;13:721s-6s.
28. Rodriguez PC, Hernandez CP, Quiceno D, Dubinett SM, Zabaleta J, Ochoa JB, Gilbert J, Ochoa AC. Arginase I in myeloid suppressor cells is induced by COX-2 in lung carcinoma. J Exp Med 2005;202:931-9.
29. Rodriguez PC, Quiceno DG, Ochoa AC. L-arginine availability regulates T -lymphocyte cell progression. Blood 2007;109:1568-73.